How many FDA-approved drugs are there?
Products, active ingredients, novel drugs and biologics, counted from FDA data
Matic Broz, PhD8 min
About 26,900 FDA-approved drug products are on the US market today as prescription or over-the-counter medicines, by our count of the FDA's Drugs@FDA data dated October 23, 2026. Strip away the extra strengths, dosage forms and generic copies and those products contain about 2,170 distinct active ingredients.
Counted as genuinely new medicines, the FDA's drug center has approved 1,434 novel drugs since 1985: 46 in 2025 and 47 more in 2026 through October 20. Vaccines, blood products and cell and gene therapies are licensed by a separate FDA center and sit outside all of these figures.
How many FDA-approved drugs are there?
Drugs@FDA, the agency's database of approved human drugs, held 51,925 product records in its October 23, 2026 data files. We counted 26,899 of them with a current marketing status: 26,088 prescription products and 811 over-the-counter products. The rest are 23,609 discontinued records and 1,417 tentative approvals.[1]
A product record is one strength and dosage form under one application, so the same medicine appears many times. Generic copies dominate: 20,821 of the active products belong to abbreviated new drug applications (ANDAs), the route for generics, against 5,321 under new drug applications (NDAs) and 752 under biologics license applications (BLAs).[1] Grouping products step by step shrinks the total from about 27,000 to about 2,200.
| What is counted | Count | Data date |
|---|---|---|
| Currently marketed product records (prescription and OTC) | 26,899 | Oct 23, 2026 |
| Applications with at least one marketed product | 14,062 | Oct 23, 2026 |
| Distinct drug names | 4,567 | Oct 23, 2026 |
| Distinct active ingredient entries, as written | 2,355 | Oct 23, 2026 |
| Distinct active ingredients, combinations split | 2,174 | Oct 23, 2026 |
| Novel drugs approved by CDER since 1985 | 1,434 | Oct 20, 2026 |
| Novel drugs approved by CDER in 2026 | 47 | Oct 20, 2026 |
| Licensed CBER biologics (vaccines, blood products, cell and gene therapies) | 326 | Sep 30, 2026 |
The FDA's own rounded figure is "over 20,000 prescription drug products approved for marketing", from a 2020 fact sheet.[5] Our count is the dated version of the same idea.
The Orange Book, the FDA's list of drugs approved on the basis of safety and effectiveness, gives a close cross-check. Its September 2026 data files list 25,579 prescription and OTC product records, all under NDAs and ANDAs. Drugs@FDA lists 26,147 once its 752 biologic products are set aside, so the two sources agree within about 2%.[6][1]
How many unique drugs has the FDA approved?
About 2,200 active ingredients are in currently marketed FDA-approved products, but no exact count of unique molecules exists. Drugs@FDA writes each ingredient as a text entry, and those entries name salts and combinations. Its 4,567 drug names reduce to 2,355 ingredient entries, 359 of them combinations such as amlodipine besylate with valsartan.[1]
Splitting the combinations gives 2,174 distinct ingredients. That still overstates the number of molecules, because one active substance can appear in several salt forms: metoprolol is listed as metoprolol succinate, metoprolol tartrate and metoprolol fumarate.[1] Regulators also treat salts and esters as separate ingredients, and use different names for the same one, such as acetaminophen and paracetamol.[7]
Curated databases resolve those names to parent molecules, and their totals land close to ours. The NIH team that built the NCGC Pharmaceutical Collection counted 2,356 molecular entities approved for human use by the FDA in 2011.[7]
ChEMBL release 37, from May 2026, lists 2,996 parent molecules at the approved stage, 2,306 of them small molecules and 291 flagged as withdrawn.[8] ChEMBL counts approvals from the FDA, the European Medicines Agency and other regulators, so its total is not FDA-only.[9] DrugBank uses the same broad definition and listed 3,054 approved small-molecule drugs on October 24, 2026.[10]
Anyone assembling an approved-drug library for repurposing or virtual screening with AutoDock Vina should therefore decide first which regulator counts, and whether withdrawn drugs and salt forms stay in. Structures for a list of ChEMBL identifiers can be downloaded as SDF files with ChEMBL Download.
How many new drugs does the FDA approve each year?
The FDA's Center for Drug Evaluation and Research (CDER) approved 46 novel drugs in 2025, made up of 34 new molecular entities and 12 new therapeutic biologics.[2][11] By October 20, 2026 it had approved 47, already more than in all of 2025. The 47th, Hibsago (bepirovirsen), was approved that day.[3]
A novel drug contains an active ingredient never before approved or marketed in the United States.[11] For small molecules, the FDA calls this a new molecular entity (NME): an active ingredient with no previously approved active moiety.[12] Generics, new strengths, new formulations and new uses of existing drugs do not count, which is why 47 novel approvals barely move a total of 26,899 products.
The pace has risen. The FDA's compilation lists 1,387 novel approvals from 1985 through 2025. They averaged 29.7 a year from 1985 through 2015 and 46.6 a year from 2016 through 2025; the record years are 1996 and 2018, with 59 each.[2] Biologics account for much of the gain. They were 9% of novel approvals in 1986 to 1990 and 31% in 2021 to 2025.[2]
Antibodies are the largest biologic class. By our count of the FDA Purple Book, the agency had licensed 159 monoclonal antibody products by September 2026.[4] Each novel approval is the end of a long pipeline: reaching it commonly takes 10 to 15 years and hundreds of millions to billions of dollars once failed programs are included.
What about vaccines and other biologics?
Drugs@FDA and the CDER counts above leave out products regulated by the Center for Biologics Evaluation and Research (CBER).[13] That center licenses vaccines, plasma-derived and recombinant blood proteins, allergen extracts, and cell and gene therapies such as voretigene neparvovec.
The Purple Book, the FDA's database of licensed biological products, covers both centers. Its September 2026 release lists 326 licensed CBER biologics license applications, plus 58 that are revoked. CDER holds 335 licenses for reference biologics and 95 for biosimilars in the same file.[4] The Purple Book sends users elsewhere for blood bank and source plasma products, so the CBER figure is a floor rather than a complete census.
Does FDA approval mean a drug is still sold?
No. Drugs@FDA keeps historical records, and its October 2026 data contain 23,609 discontinued product records, almost as many as the marketed ones.[1] The FDA lists approved products as discontinued when they were never marketed, are made only for military use or export, or had approval withdrawn for reasons other than safety after being discontinued.[12]
The same files hold 1,417 tentative approvals. A tentative approval means a generic is ready for approval but is blocked by patents or exclusivity, and the applicant cannot market it yet.[12] Approved-drug libraries built from FDA records can therefore include products that are not sold, so studies should say whether they kept discontinued drugs.
Where to find the FDA list of approved drugs
The FDA does not publish one list of every approved drug. It publishes four, each built for a different question.
| List | What it covers | Best for |
|---|---|---|
| Drugs@FDA | Prescription, generic, OTC and many CDER biologic products, with labels and approval history | Checking whether a drug is approved and when |
| Orange Book | NDA and ANDA products approved for safety and effectiveness, with patents and exclusivity; data files updated monthly | Generic equivalents and patent dates |
| Purple Book | Licensed biologics from CDER and CBER, including biosimilars and interchangeable products | Antibodies, vaccines, biosimilars |
| Novel Drug Approvals | New molecular entities and new therapeutic biologics approved by CDER, one page per year | New medicines approved this year |
To check one medicine, search Drugs@FDA by brand or ingredient name, or the Purple Book for a vaccine or other biologic. To count drugs, download the data files rather than the search pages. Our analysis script, summary counts and novel approvals by year reproduce every figure above from the dated FDA files.
